Milošević, Verica (7005575981)Verica (7005575981)MiloševićSekulić, Milka (56363527300)Milka (56363527300)SekulićBrkić, Branislava (6603788491)Branislava (6603788491)BrkićLovren, Mirjana (6603702956)Mirjana (6603702956)LovrenStarčević, Vesna (7005374307)Vesna (7005374307)Starčević2025-06-122025-06-122000https://doi.org/10.1023/A:1004158412915https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033694567&doi=10.1023%2fA%3a1004158412915&partnerID=40&md5=eb95fc1b8be45365a30f0cee04a6fa88https://remedy.med.bg.ac.rs/handle/123456789/1485The effects of intracerebroventricularly administered somatostatin (SRIH-14 or -28) on growth and function of pituitary thyrotropes (TSH-cells) were examined in adult male Wistar rats. The animals were implanted with an intracerebroventricular cannula and after a recovery period, administered three 1 μg doses of SRIH-14 or -28 dissolved in 5 μl saline every second day. Controls were treated in the same way with the same volume of saline only. TSH-producing cells were studied using the peroxidase-antiperoxidase immunohistochemical procedure. Blood samples were collected for hormone (TSH) analyses 5 days after the last injection. Both SRIH-treatments significantly decreased (p < 0.05) all morphometric parameters obtained for TSH-cells in comparison with controls. The volume of TSH-cells decreased by 27%, nuclei by 44% and volume density by 33% in animals treated with SRIH-14. In animals treated with SRIH-28, these parameters were also significantly decreased (p < 0.05) (22%, 31%, and 25% respectively) compared to control rats. Serum concentrations of TSH were significantly decreased (p < 0.05) by 15% in SRIH-14- and by 12% in SRIH-28-treated animals in comparison with the controls. These observations suggest that centrally administered SRIH-14 or -28 is specifically involved in the control of growth and secretory activity of TSH cells.